Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05054907
Other study ID # 202105097RIND
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 23, 2021
Est. completion date April 30, 2023

Study information

Verified date November 2022
Source National Taiwan University Hospital
Contact Jen-Hsuan Liu, MD
Phone +886922068868
Email b98401001@ntu.edu.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is going to use wearable devices and smartphones to collect physical data from terminal patients and build a survival predicting model for terminal patients with machine learning. Investigators hypothesize that continuous physical data monitoring could offer a hint to better predictability in end-of-life care.


Description:

The study aim to examine the feasibility of utilizing wearable devices and smartphones in palliative patients in Taiwan. In addition, investigators try to identify the relationship between mobile health data and disease progression and establish a predicting model to the emergent medical need and death of patients, via machine learning. This is a single-arm observational study using wearable devices and smartphones in terminal cancer patients. Investigators planned to enroll 75 patients who receive palliative care. After obtaining consent from the patients or their legally authorized surrogate decision-makers, a baseline assessment will be conducted, with a guide to use wearable devices and phone apps. Investigators will keep regular follow-up for 52 weeks or until the participants' death. Assessment will be conducted every week, face-to-face or by telephone contact. A routine assessment includes symptoms and functionality in the past week, and vital signs and facial photograph will be recorded if possible. Physical data measured from wearable devices would be recorded continuously. The emergent medical needs of patient, including emergency department visit, unplanned admission and death of participants will be recorded if happen. The primary outcome is the predictive performance (sensitivity and specificity) of the machine-learning model using wearable device data and symptoms assessment. The secondary outcomes are symptoms, including pain, dyspnea, diarrhea, constipation, nausea, vomiting, insomnia, depression, anxiety and fatigue. Users' opinion and comment to using experience will also be recorded.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date April 30, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 105 Years
Eligibility Inclusion criteria - Age: 20 years old or older - Clinical diagnosis: cancer in terminal stage. Exclusion criteria - Cannot cooperate with use of wearable devices or smartphones.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei
Taiwan National Taiwan University, Cancer Center Taipei

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital National Taiwan University

Country where clinical trial is conducted

Taiwan, 

References & Publications (1)

Pavic M, Klaas V, Theile G, Kraft J, Tröster G, Blum D, Guckenberger M. Mobile Health Technologies for Continuous Monitoring of Cancer Patients in Palliative Care Aiming to Predict Health Status Deterioration: A Feasibility Study. J Palliat Med. 2020 May;23(5):678-685. doi: 10.1089/jpm.2019.0342. Epub 2019 Dec 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Comparison of AUC-ROC in survival prediction between machine learning model and Palliative Performance Scale (PPS) Palliative performance scale (PPS) will be regularly assessed during the follow-up. The AUC-ROC of using PPS for survival prediction will be calculated and compared with the machine-learning model. From date of enrollment until the date of death, or assessed up to 26 weeks. PPS are assessed every week. Death or survival is recorded at the time the case closed.
Other Comparison of AUC-ROC in survival prediction between machine learning model and Glasgow Prognostic Score (GPS) Glasgow Prognostic Score (GPS) will be assessed if C-reactive protein (CRP) and albumin are examined during the follow-up. The AUC-ROC using GPS for survival prediction will be calculated and compared with the machine-learning model. GPS assessed retrospectively if data available. Death or survival is recorded at the time the case closed.
Other Comparison of AUC-ROC in survival prediction between machine learning model and Palliative Prognostic Index (PPI) Palliative Prognostic Index(PPI) will be regularly assessed during the follow-up. The AUC-ROC of using PPI for survival prediction will be calculated and compared with the machine-learning model. From date of enrollment until the date of death, or assessed up to 26 weeks. PPI are assessed every week. Death or survival is recorded at the time the case closed.
Other Comparison of AUC-ROC in survival prediction between machine learning model and Palliative Prognostic Score (PaP) Palliative Prognostic Score (PaP) will be assessed if laboratory data available during the follow-up. The AUC-ROC of using PaP for survival prediction will be compared with the machine-learning model. From date of enrollment until the date of death, or assessed up to 26 weeks. PaP assessed every week only if the laboratory data available.
Other Time spent at medical service If unexpected medical needs happen, investigators will record time spent at ER stay or hospital admission Recorded when events happen or afterwards
Other Duration between events Investigators will record duration between events (death, unexpected medical needs, admission and discharge) or duration from enrollment to events, if they happen From date of enrollment until the date of death, or assessed up to 26 weeks. Duration was calculated after cases closed.
Other Overall survival and survival time Investigators will record the overall survival and survival time from enrollment. From date of enrollment until the date of death, or assessed up to 26 weeks. Calculated after all cases closed.
Other Site of death If patient died during the follow-up, investigator will record the site of death (at home or any other chosen place, in the hospital or ER). Other details will be recorded if the family or caregivers are willing to provide. Assessed at the time the case closed, only if the patient died
Other Tolerability and user experience to wearable devices Investigator will ask and record any discomfort or side effect noted during the follow-up and at the end of the study. Investigator will survey for user experience of patients or caregivers at the end of the study. Assessed at the time the case closed
Other Relation between personal background and user experience of wearable devices Personal background such as educational level, age, and previous use of technological product will be recorded. Investigator will explore the relation between these factors and the user experience. Assessed at the time the case closed
Primary Area Under the Receiver Operating Characteristic curve (AUC-ROC) of the machine-learning model to predict survival using wearable device parameters and clinical assessment Measured data from wearable device and regular assessment (including medical condition, laboratory data, symptom, functional assessment) will be integrated to build one machine-learning model to predict patients' death or survival within specific time range. The primary outcome is to evaluate the Area Under the Receiver Operating Characteristic curve (AUC - ROC) of the machine-learning model in predicting patients' survival. From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Other clinical assessments are performed every week. Death or survival is recorded at the time the case closed.
Primary Area Under the Receiver Operating Characteristic curve (AUC-ROC) of machine-learning model to predict unexpected medical needs using wearable device parameters and clinical assessment Measured data from wearable device and regular assessment (including medical condition, laboratory data, symptom, functional assessment) will be integrated to build one machine-learning model to predict patient's unexpected medical needs (which is defined as emergency department visit or unplanned admission to hospital).
The primary outcome is to evaluate Area Under the Receiver Operating Characteristic curve (AUC-ROC) of the machine-learning model in predicting unexpected medical needs.
From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Other clinical assessments are performed every week. Events are recorded upon happening or afterwards.
Secondary Correlation between symptoms and wearable device parameters The severity of symptoms will be recorded by symptoms assessment scale (SAS). Investigators will explore the correlation between the wearable device parameters and symptoms. From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Symptoms assessed every week.
Secondary Correlation between Australia-modified Karnofsky Performance Status (AKPS) and wearable device parameters The functional status will be assessed by Australia-modified Karnofsky Performance Status (AKPS) during the follow-up. Investigators will explore the correlation between AKPS and wearable device parameters From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Functional status assessed every week.
Secondary Correlation between palliative care phase and wearable device parameters Evaluation of palliative care phases from the Palliative Care Outcomes Collaboration (PCOC) system will be assessed regularly. Investigators will explore the correlation between the palliative care phases and other parameters (wearable device parameters, symptoms, medical condition). From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Palliative care phase assessed every week.
See also
  Status Clinical Trial Phase
Recruiting NCT03679182 - Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care Phase 2
Enrolling by invitation NCT05407844 - Community Health Worker Based Intervention to Improve Palliative Care N/A
Active, not recruiting NCT04942756 - GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients. N/A
Completed NCT04821466 - VR for Symptom Control and Wellbeing N/A
Recruiting NCT04016038 - Psychosocial Approach and Sedation Practices
Completed NCT02151214 - Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer. N/A
Completed NCT04495530 - Information Needs Around Parenteral nUTrition in Cancer
Completed NCT01912846 - An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients N/A
Recruiting NCT06072612 - Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. Phase 3
Recruiting NCT03387436 - The "Hand-in-Hand Study": Improvement of Quality of Life in Palliative Cancer Patients Through Collaborative Advance Care Planning N/A
Recruiting NCT04883879 - Artificial Intelligence-based Mortality Prediction Among Cancer Patients in the Hospice Ward